Romanian drug producer Antibiotice ended the first six months of this year with sales revenues of RON 149.7 million (EUR 33.5 million), up 6 percent compared to the same period the previous year. Its gross profit also increased in this period, to 21.8 million (EUR 4.8 million), this representing a year-on-year growth of 19 percent.

“We implemented the strategy and policies in the business plan for 2012-2016, so Antibitiotice’s good results in the first half of the year were registered due to the policy to expand its portfolio, but also to the orientation towards foreign markets, where the profitability is increasing," said Ioan Nani, general manager of Antibiotice.

In the first half of this year, Antibiotice was the fifth largest producer of generic drugs without prescription in Romania. The drug producer ranks 12th on the overall pharma market in Romania.

The company’s main shareholders are the Romanian Health Ministry, with a 53 percent stake, and investment company SIF Oltenia, with 12 percent.

Irina Popescu, irina.popescu@romania-insider.com